Evidence map›Paper›PMID 41164885›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Plasma and feces multiomics unveil cognition-associated perturbations of chronic inflammatory pathways of the gut-microbiota-brain axis.

Farideh Hosseinkhani, Claire Chevalier, Moira Marizzoni, Rahel Park, Sabine Bos, Alida Kindt Dunjko, Cornelia M van Duijn, Amy C Harms, Giovanni B Frisoni, Thomas Hankemeier

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Frontiers in pharmacology · 2026
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Farideh HosseinkhaniLeiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands.
Claire ChevalierLaboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.
Moira MarizzoniLaboratory of Biological Psychiatry, IRCCS Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy.
Rahel ParkLaboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.
Sabine BosLeiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands.
Alida Kindt DunjkoLeiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands.
Cornelia M van DuijnDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, Netherlands.
Amy C HarmsLeiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands.ORCID 0000-0002-2931-4295
Giovanni B FrisoniLaboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.
Thomas HankemeierLeiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands.

Funding

Clinical Research Center, University Hospital and Faculty of MedicineDutch Research Council (NWO) 175.2019.032Dutch Research Council (NWO) 184.034.019Fondation AETAS, GenèveFondation Child Care, GenèveFondation Edmond J. Safra, GenèveFondation Minkoff, GenèveFondation Segré, GenèveFondazione Agusta, LuganoHôpitaux Universitaires de GenèveItalian Ministry of Health (Ricerca Corrente)McCall Macbain Foundation, CanadaNederlandse Organisatie voor Wetenschappelijk Onderzoek 175.2019.032Nicole et René Keller, GenèvePrivate Foundation of Geneva University Hospitals: A.P.R.A.-Association Suisse pour la Recherche sur la Maladie d'Alzheimer, GenèveRace Against Dementia Foundation, London, UK
6 · The paper itself

Abstract

introductionGut-microbiota dysbiosis has been linked to cognitive decline. Given its role in metabolism, immunity, and environmental interactions, broader molecular signaling alterations are likely.

methodsWe analyzed gut microbiota composition, plasma and fecal metabolites, and inflammatory cytokines across cognitive stages, from healthy controls to dementia.

resultsAlpha diversity declined with increasing cognitive impairment severity. Short-chain fatty acid-producing Firmicutes and Bacteroidota decreased from 76% and 17% in controls to 59% and 11% in dementia, respectively. Proteobacteria (e.g., Escherichia-Shigella) rose from < 2% to 4%, and Verrucomicrobiota from 3% to 11%. Despite overall Firmicutes decline, Ruminococcus gnavus, a mucus-degrading species, increased in dementia. These shifts correlated with elevated plasma cytokines, suggesting a link between gut dysbiosis and systemic inflammation. Bacteria-associated metabolites, including bile acids, trimethylamine N-oxide, oxylipins, sugars, and fatty acids were significantly altered. Changes were seen as early as subjective cognitive decline. DISCUSSION: Larger studies are needed to validate these findings and explore microbiome-based interventions. HIGHLIGHTS: Examined gut microbiota, inflammation, and metabolic changes in cognitive impairment stages Early metabolic changes in feces detected before plasma alterations Observed shifts in gut microbiota and inflammation associated with cognitive decline Suggests potential for early biomarkers based on gut metabolites Calls for larger, longitudinal studies to validate findings.

Indexed as

BrainCognitive DysfunctionDysbiosisFecesGastrointestinal MicrobiomeInflammationAgedCytokinesFemaleHumansMaleMultiomicsCytokinesAlzheimer's diseasegut‐brain axisgut microbiotametabolomicsmetagenomics

Identifiers

PMID41164885
PMCPMC12572818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.